

## Original Research Article

# COMPARATIVE STUDY OF THE EFFICACY OF COMBINED FRACTIONAL CO<sub>2</sub> LASER AND TOPICAL 0.1% TACROLIMUS OINTMENT VERSUS TOPICAL 0.1% TACROLIMUS OINTMENT ALONE IN NON-SEGMENTAL VITILIGO

Sanket Ghanate<sup>1</sup>, Farzana Md<sup>2</sup>, Rahul Ray<sup>3</sup>, Kollipara Haritha<sup>4</sup>, B.V. Ramachandra<sup>5</sup>

<sup>1</sup>Senior Resident, LTMMC & Sion hospital, Mumbai, India.

<sup>2</sup>Associate Professor, GITAM Institute of Medical Sciences and Research (GIMSR), Visakhapatnam, India.

<sup>3</sup>Professor & HOD, GIMSR, Visakhapatnam, India.

<sup>4</sup>Associate Professor, GIMSR, Visakhapatnam, India.

<sup>5</sup>Professor & HOD (Retd), GIMSR, Visakhapatnam, India.

Received : 11/07/2025  
Received in revised form : 27/08/2025  
Accepted : 15/09/2025

## Corresponding Author:

Dr. Sanket Ghanate,  
Senior Resident, LTMMC & Sion  
hospital, Mumbai, India..

DOI: 10.70034/ijmedph.2025.4.39

Source of Support: Nil,

Conflict of Interest: None declared

Int J Med Pub Health  
2025; 15 (4); 214-219

## ABSTRACT

**Background:** The clinical manifestation of Vitiligo, an acquired pigmentary condition, is depigmented macules brought on by melanocyte loss. Although there are many other treatment options, fractional carbon dioxide (CO<sub>2</sub>) lasers, which operate on the basis of photothermolysis, have lately been tested with positive results. **Objective:** To evaluate the effectiveness of topical 0.1% tacrolimus ointment plus fractional CO<sub>2</sub> laser versus topical 0.1% tacrolimus ointment alone in non-segmental vitiligo.

**Materials and Methods:** Eighty patients with stable non-segmental vitiligo were enrolled in this interventional prospective study conducted over a period of two years. They were divided into two groups of forty patients each. For three months, Group A received topical 0.1% tacrolimus twice daily and fractional CO<sub>2</sub> laser treatments every month while Group B received only 0.1% topical tacrolimus twice daily. Re-pigmentation was evaluated clinically and dermoscopically at monthly intervals for the first three months and again at the conclusion of six months.

**Results:** Of the eighty patients in this study, thirty-two were males, and forty-eight were females. Group A's mean age was  $33.25 \pm 11.8$  years, while group B's was  $31.98 \pm 11.13$  years. In both groups, the average duration of disease was  $4.8 \pm 4.83$  years. According to the Quartile Grading Scale (QGS), at six months, there was a statistically significant difference ( $p < 0.05$ ) in QGS with fifteen patients (60%) in Group A and nine patients (27.2%) in Group B showing more than 50% re-pigmentation. On dermoscopic evaluation at the end of six months, eighteen patients (72%) in Group A and fourteen patients (42.4%) in Group B showed moderate to good response in DAG which was statistically significant ( $p < 0.05$ ).

**Conclusion:** Both clinical and dermoscopic assessments demonstrated that re-pigmentation was significantly enhanced with the combination of fractional CO<sub>2</sub> laser and topical tacrolimus 0.1%. These findings suggest that fractional CO<sub>2</sub> laser may serve as an effective therapeutic option for the management of stable vitiligo.

**Keywords:** Fractional CO<sub>2</sub> laser, 0.1% Tacrolimus, Vitiligo.

## INTRODUCTION

Vitiligo is a chronic, polygenic, acquired, autoimmune disorder of depigmentation causing selective loss of melanocytes, leading to depigmentation over affected skin.<sup>[1,2]</sup> Its prevalence is 0.4 to 2% of the population worldwide and 0.25% to 4% in India.<sup>[3]</sup> These lesions affect both genders and are totally amelanotic white macules, having a significant psychological impact on day-to-day life.<sup>[4]</sup> Clinically, it manifests as depigmented, chalky white macules with distinct borders that can develop at any age or site on the body but are most common on the face, forearms, hands, fingers, and scalp. The lesions vary from a few millimetres to several centimetres in size, with well-demarcated convex borders. Numerous pathogenic processes have been proposed to cause vitiligo, including oxidant-antioxidant hypotheses, autoimmunity, neural theory, and melanocytorrhagy.<sup>[5]</sup> Many treatment modalities have been used based on disease severity, disease stability as well as lesional stability, personal preference, financial status, and convenience of follow-up.<sup>[6]</sup> Topical therapy is preferred for localized lesions, whereas systemic treatment is indicated for patients with more than 10% body surface area (BSA) involvement or those with unstable and progressive disease. Surgical modalities are reserved for stable vitiligo that is recalcitrant to medical treatment.

Despite the treatments available, many patients with vitiligo remain in a refractory state. Therefore, various modalities combining conventional and newer therapeutic regimens are essential for enhancing the treatment outcome. Recently, a combination of fractional carbon dioxide (CO<sub>2</sub>) laser with topical tacrolimus, 5-fluorouracil (5-FU) and narrow band ultraviolet-B (NB-UVB) therapy has been used to enhance early response. Topical tacrolimus has been preferred for ages for the treatment of vitiligo due to its immunosuppressive action by calcineurin inhibition and fewer side effects.<sup>[7]</sup> However, the single use of topical tacrolimus alone may not be practical due to inadequate penetration due to its high molecular weight. Ablative therapies, like fractional CO<sub>2</sub> laser, have been tried to enhance the penetration of topical drugs by creating microscopic thermal zones (MTZ). Laser produces fractional photo-thermolysis, which activates the cytokine inflammatory cascade and is responsible for the proliferation and differentiation of melanocytes [8]. In this study, the effectiveness of fractional CO<sub>2</sub> laser and topical 0.1% tacrolimus versus topical 0.1% tacrolimus ointment alone was compared for non-segmental vitiligo.

## MATERIALS AND METHODS

This interventional prospective study on eighty patients of non-segmental vitiligo attending the Dermatology, Venereology, and Leprosy outpatient department of a tertiary care center, was conducted

from August 2022 to May 2024. The patients were divided into two groups of forty patients each. Group A was treated with a combination of fractional CO<sub>2</sub> laser and topical 0.1% tacrolimus. Group B was treated with topical 0.1% tacrolimus only. Patients with non-segmental vitiligo aged 10–50yrs who had not received topical or systemic therapy in the previous three months were included. Exclusion criteria were, presence of leucotrichia, pregnancy and lactation, keloids and hypertrophic scars, and any current infections, eczema or psoriasis. The institutional ethics committee approved the study with the reference number – IEC-79/2022. Prior to the study, all patients provided written informed consent, demographic data was recorded, complete history was obtained, general and systemic examination was performed. A thorough dermatological assessment was done and details recorded. Baseline investigations like complete blood count, fasting and post prandial blood sugar, thyroid function tests were done. Photographs were taken at baseline and monthly intervals using a smartphone (One Plus 11 R 5G, Model CPH2487). An area of <10 cm<sup>2</sup> was marked with respect to anatomical landmarks for assessing re-pigmentation at subsequent visits. Dermoscopy was performed using handheld Dermlite DL4 Dermoscope 4th generation Inc, USA.

In group A patients, before laser irradiation, the area for intervention was marked, and topical anaesthetic cream (comprising of lidocaine and prilocaine 2.5% each) was applied for 30 to 40 minutes. The site was cleaned, and eyes were protected using a gauze piece and eye shield. Laser irradiation was done by Futura RF-RF excited CO<sub>2</sub> laser 50W (fractional CO<sub>2</sub> laser) single pass at marked site with following laser parameters – energy – 15-20mJ, duration – 1ms, number of passes – spot distance 0.6mm. Post laser session, an ice pack was kept for ten minutes, and the site was examined for any pain, erythema, oedema & blistering. Three sessions of laser were done at monthly intervals, and topical 0.1% tacrolimus ointment was applied twice daily for three months.

In group B, the patients were advised to use 0.1% tacrolimus twice daily for three months. Patients in both groups were given treatment for the first three months and followed up for the next three months. Assessment for re-pigmentation and monitoring of side effects was done at monthly intervals for three months and at the end of sixth month. The treatment response was assessed clinically by Quartile Grading Scale (QGS) & by calculating the number of perifollicular spots on dermoscopy using Dermoscopic Assessment Grading (DAG).

### Statistical Analysis

The statistical analysis was performed using the Statistical Package for Social Sciences (SPSS Version 26). Descriptive statistical analysis was used to look at the distribution of specific quantitative and categorical variables. n (%) summarised categorical variables, and means and standard deviations summed quantitative factors. Each outcome was

tallied and, if required, graphically depicted using bar or pie diagrams. Categorical variables were assessed for statistical significance in the difference between the two groups using the chi-square test. A p-value <0.05 was considered statistically significant, assuming that all statistical test rules were followed.

## RESULTS

The study enrolled 80 patients with non-segmental vitiligo, comprising 32 males (40%) and 48 females (60%). Patients were randomized into two equal groups (n = 40 each). The mean age was  $33.25 \pm 11.80$  years in Group A (fractional CO<sub>2</sub> laser with

topical 0.1% tacrolimus) and  $31.98 \pm 11.13$  years in Group B (topical 0.1% tacrolimus alone). The mean disease duration was similar in both groups ( $4.84 \pm 5.29$  years for Group A;  $4.90 \pm 4.38$  years for Group B). Nine patients (11.3%) had comorbidities (3 with diabetes mellitus, 3 with hypertension, 3 with hypothyroidism). The most commonly affected anatomical sites were the legs, face/neck, forearms, hands, and trunk. A family history of vitiligo was reported in one patient from each group. The baseline Vitiligo Area Scoring Index (VASI) scores were  $171.1 \pm 127.5$  for Group A and  $136.5 \pm 71.4$  for Group B. Of the 80 enrolled patients, 22 were lost to follow-up (15 from Group A, 7 from Group B).

**Table 1: Socio-Demographic and Baseline Characteristics**

| Characteristic        | Group A (n = 40)  | Group B (n = 40)  | p-value |
|-----------------------|-------------------|-------------------|---------|
| Mean Age (years)      | $33.25 \pm 11.80$ | $31.98 \pm 11.13$ | 0.94    |
| 10-20 years, n (%)    | 8 (20.0)          | 5 (12.5)          |         |
| 21-30 years, n (%)    | 8 (20.0)          | 17 (42.5)         |         |
| 31-40 years, n (%)    | 13 (32.5)         | 7 (17.5)          |         |
| 41-50 years, n (%)    | 11 (27.5)         | 11 (27.5)         |         |
| Gender                |                   |                   | 0.50    |
| Male, n (%)           | 15 (37.5)         | 17 (42.5)         |         |
| Female, n (%)         | 25 (62.5)         | 23 (57.5)         | 0.50    |
| Mean Duration (years) | $4.84 \pm 5.29$   | $4.90 \pm 4.38$   | 0.99    |
| Comorbidities, n (%)  |                   |                   | 0.12    |
| Diabetes mellitus     | 3 (7.5)           | 0 (0)             |         |
| Hypertension          | 1 (2.5)           | 2 (5.0)           | 0.50    |
| Hypothyroidism        | 2 (5.0)           | 1 (2.5)           | 0.50    |
| Lesion Site, n (%)    |                   |                   | 0.83    |
| Face and neck         | 6 (15.0)          | 9 (22.5)          |         |
| Trunk                 | 6 (15.0)          | 4 (10.0)          |         |
| Hands                 | 5 (12.5)          | 4 (10.0)          |         |
| Forearms              | 5 (12.5)          | 7 (17.5)          |         |
| Foot                  | 1 (2.5)           | 2 (5.0)           |         |
| Legs                  | 17 (42.5)         | 14 (35.0)         |         |
| Family history, n (%) | 1 (2.5)           | 1 (2.5)           | 0.73    |
| VASI (mean $\pm$ SD)  | $171.1 \pm 127.5$ | $136.5 \pm 71.4$  | 0.14    |

**Table 2: Quartile Grading Scale for Clinical Re-pigmentation**

| Grade | Percentage of Re-pigmentation | Clinical Response |
|-------|-------------------------------|-------------------|
| 0     | 0%                            | Nil               |
| 1     | 1–25%                         | Minimal           |
| 2     | 26–50%                        | Moderate          |
| 3     | 51–75%                        | Good              |
| 4     | >75%                          | Excellent         |

**Table 3: Comparative Quartile Grading Scale (QGS): Percentage of Patients Achieving  $\geq 50\%$  Re-pigmentation at Each Follow-up**

| Time Point  | Group A (n = 25)                          | Group B (n = 33)                         | p-value      |
|-------------|-------------------------------------------|------------------------------------------|--------------|
| First month | <50% re-pigmentation<br>24 (96.0%)        | <50% re-pigmentation<br>31 (93.9%)       | 0.70         |
|             | $\geq 50\%$ re-pigmentation<br>1 (4.0%)   | $\geq 50\%$ re-pigmentation<br>2 (6.1%)  |              |
| Third month | <50% re-pigmentation<br>18 (72.0%)        | <50% re-pigmentation<br>28 (84.8%)       | 0.20         |
|             | $\geq 50\%$ re-pigmentation<br>7 (28.0%)  | $\geq 50\%$ re-pigmentation<br>5 (15.2%) |              |
| Sixth month | <50% re-pigmentation<br>10 (40.0%)        | <50% re-pigmentation<br>24 (72.7%)       | <b>0.01*</b> |
|             | $\geq 50\%$ re-pigmentation<br>15 (60.0%) | $\geq 50\%$ re-pigmentation<br>9 (27.3%) |              |

\*Statistically significant at  $p < 0.05$

**Table 4: Dermoscopic Assessment Grading (DAG) Criteria**

| Grade of Re-pigmentation | Number of Perifollicular Spots |
|--------------------------|--------------------------------|
| No response              | 0                              |
| Minimal                  | 1–2                            |
| Moderate                 | 3–6                            |
| Good                     | >6                             |

**Table 5: Comparative Dermoscopic Assessment Grading (DAG): Patients Showing Moderate to Good Response at Follow-up**

| Time Point  | Response Category      | Group A (n = 25) | Group B (n = 33) | p-value      |
|-------------|------------------------|------------------|------------------|--------------|
| First month | No to minimal response | 23 (92.0%)       | 27 (81.8%)       | 0.20         |
|             | Moderate to good       | 2 (8.0%)         | 6 (18.2%)        |              |
| Third month | No to minimal response | 12 (48.0%)       | 20 (60.6%)       | 0.30         |
|             | Moderate to good       | 13 (52.0%)       | 13 (39.4%)       |              |
| Sixth month | No to minimal response | 7 (28.0%)        | 19 (57.6%)       | <b>0.02*</b> |
|             | Moderate to good       | 18 (72.0%)       | 14 (42.4%)       |              |

\*Statistically significant at  $p < 0.05$ . Percentages are based on patients who completed follow-up at each interval.


The baseline demographic and clinical variables were comparable between the two treatment groups (Table 1). The mean ages were  $33.25 \pm 11.80$  years for Group A and  $31.98 \pm 11.13$  years for Group B ( $p = 0.94$ ). Gender distribution, disease duration, and lesion sites showed no significant differences, indicating balanced groups for comparison. Comorbidities such as diabetes mellitus, hypertension, and hypothyroidism were infrequent and similarly distributed ( $p > 0.05$ ). The mean Vitiligo Area Scoring Index (VASI) scores were also comparable ( $171.1 \pm 127.5$  in Group A versus  $136.5 \pm 71.4$  in Group B,  $p = 0.14$ ), confirming equivalent disease severity at baseline.

The Quartile Grading Scale (QGS) categorizes re-pigmentation into five grades ranging from nil (0% re-pigmentation) to excellent ( $>75\%$ ) (Table 2). This scale was used to quantify clinical response, facilitating a standardized, semi-quantitative assessment of treatment efficacy based on percentage of re-pigmentation.


Clinical evaluation demonstrated progressively increasing proportions of patients achieving  $\geq 50\%$  re-pigmentation in both groups over time (Table 3). At 1 and 3 months, differences between Group A and Group B were not statistically significant ( $p = 0.70$  and  $0.20$ , respectively). However, by 6 months, Group A showed a significantly higher rate of patients with  $\geq 50\%$  re-pigmentation (60.0%) compared to Group B (27.3%) ( $p = 0.01$ ), indicating superior clinical response with the combination of fractional CO<sub>2</sub> laser and topical tacrolimus.

The DAG system quantifies perifollicular pigmentation via the number of perifollicular pigmented spots, categorizing re-pigmentation response as no response (0 spots), minimal (1–2 spots), moderate (3–6 spots), or good ( $>6$  spots) (Table 4). This dermoscopic grading offers an objective and sensitive method to evaluate follicular re-pigmentation during treatment monitoring.


Dermoscopic analysis mirrored clinical findings, with an increasing percentage of patients showing moderate to good perifollicular re-pigmentation over time in both groups (Table 5). At 1 and 3 months, no statistically significant differences were observed between groups ( $p = 0.20$  and  $0.30$ , respectively). By 6 months, however, Group A demonstrated a significantly higher proportion of moderate to good responses (72.0%) compared to Group B (42.4%) ( $p = 0.02$ ), supporting enhanced treatment efficacy with combined fractional CO<sub>2</sub> laser and topical tacrolimus therapy.



**Figure 1: Line graph showing re-pigmentation in QGS between Group A and Group B in the first, third and sixth month**




**Figure 2: Line graph showing re-pigmentation in DAG between Group A and Group B in the first, third and sixth month**




**Figure 3: Clinical pictures showing QGS response in Group A at baseline (3a), third month (3b), and sixth month (3c) on the upper back**






**Figure 4: Dermoscopy pictures showing DAG response in Group A at baseline (5a), third month (5b), sixth month (5c) over the upper back**



**Figure 5: Clinical pictures showing QGS response in Group B at baseline (4a), third month (4b), sixth month (4c) on the left leg**



**Figure 6: Dermoscopy pictures showing DAG response in Group B at baseline (6a), third month (6b), and sixth month (6c) on the left leg**

## DISCUSSION

Vitiligo is a chronic, autoimmune disorder of pigmentation presenting with multiple, polysized depigmented macules. It is associated with deep psychological stress and social stigma pertaining to its unpleasant appearance.<sup>[9]</sup>

The mean age was  $32.61 \pm 11.46$  years, out of which the majority of patients were females, comparable to research published by Zeid et al. and Silpa-Archa et al.<sup>[10,11]</sup> This could be due to the cosmetic and social reasons faced by the women in society, which makes them come early for the treatment. However, the study by Bae et al. showed male predominance.<sup>[12]</sup> In contrast to the study by Silpa-Archa et al., the mean disease duration was  $4.87 \pm 4.83$  years.<sup>[11]</sup>

In this study, out of eighty patients, nine patients had an association with comorbidities. Among these nine patients, three (3.75%) were diabetic, three (3.75%)

hypertensive, and three (3.75%) hypothyroid. In a systematic review and meta-analyses by Ji ha Lee et al., vitiligo patients had an increased chance of developing diabetes mellitus compared to hypertension. Also, vitiligo patients had increased chances of having autoimmune thyroiditis followed by hypothyroidism & hyperthyroidism.<sup>[13]</sup> Only three of the eighty patients in this study had hypothyroidism, although a study by Gopal et al. found a 12% correlation between vitiligo and thyroid disorders.<sup>[14]</sup> In contrast to the study by Shajil EM et al., which found familial occurrence to be between 6.25% to 30%, only 5% of the study population had a family history of vitiligo, with just one patient per group having this condition.<sup>[15]</sup>

According to the Quartile Grading Scale (QGS), seven patients (28%) in Group A and five patients (15.15%) in Group B achieved more than 50% re-pigmentation at the end of third month. At the end of the sixth month, more than 50% re-pigmentation in QGS was demonstrated in 60% of Group A patients and 27.2% of Group B patients, thus showing significant ( $p < 0.05$ ) re-pigmentation in group A than group B. A study by Manzoor et al. on one-hundred and twenty patients of segmental vitiligo showed significant re-pigmentation with an efficacy of 56.7% in the fractional CO<sub>2</sub> laser group than tacrolimus alone.<sup>[16]</sup> Similarly, a study by Putta et al. showed significant re-pigmentation when a combination therapy of fractional CO<sub>2</sub> laser, topical 0.1% tacrolimus and NB-UVB was used.<sup>[17]</sup>

In this study, lesions over the lower extremities and trunk showed early improvement in QGS and DAG in group A as compared to the acral areas, contrary to Zeid et al. study, where both the groups showed better re-pigmentation at head and neck areas.<sup>[10]</sup> In a study by V Brazelli et al. grade 4 (75%) response was seen in both young and older age groups over the face, but over neck grade 4 (75%) re-pigmentation occurred earlier in younger patients as compared to older patients.<sup>[19]</sup> Similar to the study by Patil et al., males showed poor therapeutic prognosis compared to females.<sup>[20]</sup>

On dermoscopy, various patterns of re-pigmentation were seen, such as perilesional, perifollicular, and reticular pigmentation. Among these, a perifollicular pattern of re-pigmentation was seen in both groups, which was assessed using DAG. In a study by Lui Mei et al., the efficacy of treatment was assessed using dermoscopic perifollicular re-pigmentation, showing that dermoscopic assessment was superior to conventional visual observation.<sup>[18]</sup> On dermoscopic evaluation at the end of third month using Dermoscopic Assessment Grading (DAG), thirteen patients each in Group A (52%) and Group B (39.3%) demonstrated a moderate to good response. At the end of the sixth month, moderate to good response in DAG was shown by 72% of group A patients and 42.4% of group B patients, projecting a significant difference ( $p < 0.05$ ). Early perifollicular re-pigmentation was appreciated in group A rather than group B.

Moderate to good improvement (more than 50% response) in QGS was more in the fractional CO<sub>2</sub> laser and tacrolimus group (group A) compared to tacrolimus alone group (group B). The reasons for re-pigmentation could be, first, CO<sub>2</sub> laser ablation, causing tissue retraction and shrinkage due to collagen bundle denaturation.<sup>[17]</sup> Second, initiating re-pigmentation by proliferation, activation & movement of melanoblasts from the outer root sheath of hair follicles on melanoreceptors from the border area towards the depigmented area. Third, it enhances matrix metalloproteinases 2 and 9 production, causing melanocyte migration from adjacent skin.<sup>[10]</sup> The lesser response in group B may be attributed to the "500 Dalton rule", impairing effective absorption of tacrolimus due to its high molecular weight (822Da). Response in the fractional CO<sub>2</sub> group was better than tacrolimus alone, which could be due to the better penetration of tacrolimus through MTZ's created by fractional CO<sub>2</sub> laser.<sup>[8]</sup> More than 50% re-pigmentation was seen in patients aged more than fifteen years.

In this study, pain and erythema were the common side effects seen in group A and pruritus in group B, which subsided spontaneously during subsequent visits. Crusting was present in most of our patients post-laser, and it disappeared in 7-10 days. Similarly, in the Zeid et al. study, all the patients receiving fractional CO<sub>2</sub> laser experienced pain and erythema as a common side effect.<sup>[10]</sup> Few patients were lost to follow-up due to various reasons like financial constraints, slower response, frequent hospital visits, and long-term follow-up.

The limitations of this study include a small sample size, which restricts the generalizability of the findings; challenges in patient follow-up due to the slow therapeutic response, cost constraints, and the need for frequent hospital visits; and the non-randomized study design.

## CONCLUSION

A combination of fractional CO<sub>2</sub> laser and topical tacrolimus 0.1% showed significant improvement in re-pigmentation both clinically and dermoscopically. Hence, the fractional CO<sub>2</sub> laser is a ray of hope for the treatment of vitiliginous patches for focal cosmetically substantial sites. Still, more studies with larger samples and long-term follow-up are required to implement it as a new mode of intervention.

## REFERENCES

- Ezzedine K, Eleftheriadou V, Whitton M, Van Geel N: Vitiligo. *The Lancet*. 2015, 386:74–84. 10.1016/S0140-6736(14)60763-7
- Mohammed GF, Goma AH, Al-Dhubaibi MS: Highlights in pathogenesis of vitiligo. *World J Clin Cases*. 2015, 3:221–30. 10.12998/wjcc.v3.i3.221
- Krüger C, Schallreuter KU: A review of the worldwide prevalence of vitiligo in children/adolescents and adults. *Int J Dermatol*. 2012, 51:1206–12. 10.1111/j.1365-4632.2011.05377.x
- Bergqvist C, Ezzedine K: Vitiligo: A review. *Dermatology*. 2020, 236:571–92. 10.1159/000506103
- Mohamed MAE, Elgarhy LH, Elsaka AM, Elsamongy M, Nassar SO: Vitiligo: Highlights on pathogenesis, clinical presentation and treatment. *J Adv Med Med Res*. 2023, 35:165–87. 10.9734/jamr/2023/v35i195151
- Dellatorre G, Antelo DAP, Bedrikow RB, Cestari TF, Follador I, Ramos DG, Silva De Castro CC: Consensus on the treatment of vitiligo – Brazilian Society of Dermatology. *An Bras Dermatol*. 2020, 95:70–82. 10.1016/j.abd.2020.05.007
- Sisti A, Sisti G, Oranges CM: Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: A comprehensive literature review. *An Bras Dermatol*. 2016, 91:187–95. 10.1590/abd1806-4841.20164012
- Wen X, Hamblin MR, Xian Y, Li Y: A preliminary study of fractional CO<sub>2</sub> laser added to topical tacrolimus combined with 308 nm excimer lamp for refractory vitiligo. *Dermatol Ther*. 2019, 32:e12747. 10.1111/dth.12747
- Al-Smadi K, Imran M, Leite-Silva VR, Mohammed Y: Vitiligo: A review of aetiology, pathogenesis, treatment, and psychosocial impact. *Cosmetics*. 2023, 10:84. 10.3390/cosmetics10030084
- Zeid OA, Omar N, El Sharkawy D: The efficacy of combining fractional CO<sub>2</sub> laser and tacrolimus ointment in the treatment of vitiligo. *J Egypt Womens Dermatol Soc*. 2020, 17:25–30. 10.4103/JEWD.JEWD\_41\_19
- Silpa-Archa N, Nitayavardhana S, Thanomkitti K, Chularojanamontri L, Varothai S, Wongpraparut C: Comparison of the efficacy and safety of 0.1% tacrolimus ointment and 0.1% mometasone furoate cream for adult vitiligo: A single-blinded pilot study. *Dermatol Sin*. 2016, 34:177–9. 10.1016/j.dsi.2016.05.005
- Bae JM, Kim M, Lee HH, et al.: Increased risk of vitiligo following anti-tumor necrosis factor therapy: A 10-year population-based cohort study. *J Invest Dermatol*. 2018, 138:768–74. 10.1016/j.jid.2017.11.012
- Lee JH, Ju HJ, Seo JM, Almurayshid A, Kim GM, Ezzedine K, Bae JM: Comorbidities in patients with vitiligo: A systematic review and meta-analysis. *J Invest Dermatol*. 2023, 143:777–789.e6. 10.1016/j.jid.2022.10.021
- Gopal K, Rama Rao GR, Kumar YHK, Appa Rao MV, Vasudev P, Srikanth: Vitiligo: A part of a systemic autoimmune process. *Indian J Dermatol Venereol Leprol*. 2007, 73:162–5. 10.4103/0378-6323.32710
- Begum R, Shajil E, Agrawal D, Vagadia K, Marfatia Y: Vitiligo: Clinical profiles in Vadodara, Gujarat. *Indian J Dermatol*. 2006, 51:100–4. 10.4103/0019-5154.26928
- Manzoor M, Tahir K, Amin U, Bashir S, Altaf O, Naeem N: Efficacy of fractional carbon dioxide laser versus 0.1% tacrolimus cream in the treatment of segmental vitiligo. *J Pak Assoc Dermatol*. 2023, 33:943–8.
- Putta A, Javed MW: A comparative study of fractional carbon dioxide laser, narrowband ultraviolet B and topical tacrolimus 0.1% ointment versus narrowband ultraviolet B, topical tacrolimus 0.1% ointment in stable vitiligo. *Int J Res Dermatol*. 2020, 6:243–7. 10.18203/issn.2455-4529.IntJResDermatol20200605
- Wang L, Lu W, Yuan J, Zeng B, Li D, Zhang F, Li J: Utility of dermoscopy for evaluating the therapeutic efficacy of tacrolimus ointment plus 308-nm excimer laser combination therapy in localized vitiligo patients. *Exp Ther Med*. 2018, 15:3981–8. 10.3892/etm.2018.5911
- Brazzelli V, Antoninetti M, Palazzini S, Barbagallo T, De Silvestri A, Borroni G: Critical evaluation of the variants influencing the clinical response of vitiligo: Study of 60 cases treated with ultraviolet B narrow-band phototherapy. *J Eur Acad Dermatol Venereol*. 2007, 21:1369–74. 10.1111/j.1468-3083.2007.02278.x
- Patil S, Gautam M, Nadkarni N, Saboo N, Godse K, Setia MS: Gender differences in clinicoepidemiological features of vitiligo: A cross-sectional analysis. *ISRN Dermatol*. 2014, 2014:186197. 10.1155/2014/186197.